Compare CAPR & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | ANTA |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 197.7M |
| IPO Year | 2011 | N/A |
| Metric | CAPR | ANTA |
|---|---|---|
| Price | $33.11 | $7.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $41.38 | $16.17 |
| AVG Volume (30 Days) | ★ 1.1M | 3.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,270,465.00 | N/A |
| Revenue This Year | N/A | $59.06 |
| Revenue Next Year | $17,308.50 | $41.16 |
| P/E Ratio | ★ N/A | $19.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $7.30 |
| 52 Week High | $40.37 | $15.65 |
| Indicator | CAPR | ANTA |
|---|---|---|
| Relative Strength Index (RSI) | 71.31 | 32.70 |
| Support Level | $22.09 | N/A |
| Resistance Level | $40.37 | $9.83 |
| Average True Range (ATR) | 1.72 | 0.37 |
| MACD | 0.61 | -0.10 |
| Stochastic Oscillator | 71.08 | 28.20 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.